1449 related articles for article (PubMed ID: 29455320)
1. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
2. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
[TBL] [Abstract][Full Text] [Related]
3. Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease.
Kuwana M; Shirai Y; Takeuchi T
J Rheumatol; 2016 Oct; 43(10):1825-1831. PubMed ID: 27481907
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort.
Cao XY; Hu SS; Xu D; Li MT; Wang Q; Hou Y; Zeng XF
Int J Rheum Dis; 2019 Jan; 22(1):108-115. PubMed ID: 30592376
[TBL] [Abstract][Full Text] [Related]
5. Follow-up of serum KL-6 lung fibrosis biomarker levels in 173 patients with systemic sclerosis.
Kumánovics G; Görbe E; Minier T; Simon D; Berki T; Czirják L
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-138-44. PubMed ID: 24773853
[TBL] [Abstract][Full Text] [Related]
6. KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).
Sieiro Santos C; Antolín SC; Lorenzo JC; Garay CL; Morales CM; de Miguel EB; Guerrero MR; Herránz LS; Álvarez ED
Semin Arthritis Rheum; 2024 Apr; 65():152366. PubMed ID: 38290372
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis.
Kennedy B; Branagan P; Moloney F; Haroon M; O'Connell OJ; O'Connor TM; O'Regan K; Harney S; Henry MT
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):228-36. PubMed ID: 26422568
[TBL] [Abstract][Full Text] [Related]
8. The value of serum Krebs von den lungen-6 as a diagnostic marker in connective tissue disease associated with interstitial lung disease.
Ma H; Lu J; Song Y; Wang H; Yin S
BMC Pulm Med; 2020 Jan; 20(1):6. PubMed ID: 31915006
[TBL] [Abstract][Full Text] [Related]
9. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease.
Lee JS; Lee EY; Ha YJ; Kang EH; Lee YJ; Song YW
Arthritis Res Ther; 2019 Feb; 21(1):58. PubMed ID: 30764869
[TBL] [Abstract][Full Text] [Related]
10. Kinetic changes in serum KL-6 levels predict disease progression in patients with systemic sclerosis-associated interstitial lung disease.
Watanabe S; Kase K; Saeki K; Ohkura N; Murata A; Waseda Y; Takato H; Ichikawa Y; Yasui M; Kasahara K
Respir Med; 2022 Jan; 191():106689. PubMed ID: 34844174
[TBL] [Abstract][Full Text] [Related]
11. Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease.
Ko UW; Cho EJ; Oh HB; Koo HJ; Do KH; Song JW
PLoS One; 2020; 15(12):e0244114. PubMed ID: 33332430
[TBL] [Abstract][Full Text] [Related]
12. Krebs von den Lungen-6 associated with chest high-resolution CT score in evaluation severity of patients with interstitial lung disease.
Qin H; Xu XP; Zou J; Zhao XJ; Wu HW; Zha QF; Chen S; Kang Y; Jiang HD
Pulmonology; 2019; 25(3):143-148. PubMed ID: 30007895
[TBL] [Abstract][Full Text] [Related]
13. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.
Volkmann ER; Tashkin DP; Kuwana M; Li N; Roth MD; Charles J; Hant FN; Bogatkevich GS; Akter T; Kim G; Goldin J; Khanna D; Clements PJ; Furst DE; Elashoff RM; Silver RM; Assassi S
Arthritis Rheumatol; 2019 Dec; 71(12):2059-2067. PubMed ID: 31233287
[TBL] [Abstract][Full Text] [Related]
14. Lung ultrasound B-lines and serum KL-6 correlate with the severity of idiopathic inflammatory myositis-associated interstitial lung disease.
Wang Y; Chen S; Lin J; Xie X; Hu S; Lin Q; Zheng K; Du G; Huang X; Zhang G; Gargani L; Matucci-Cerinic M; Furst DE
Rheumatology (Oxford); 2020 Aug; 59(8):2024-2029. PubMed ID: 31794028
[TBL] [Abstract][Full Text] [Related]
15. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.
Suliman YA; Dobrota R; Huscher D; Nguyen-Kim TD; Maurer B; Jordan S; Speich R; Frauenfelder T; Distler O
Arthritis Rheumatol; 2015 Dec; 67(12):3256-61. PubMed ID: 26316389
[TBL] [Abstract][Full Text] [Related]
16. Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study.
Sumida H; Asano Y; Tamaki Z; Aozasa N; Taniguchi T; Toyama T; Takahashi T; Ichimura Y; Noda S; Akamata K; Saigusa R; Miyazaki M; Kuwano Y; Yanaba K; Yoshizaki A; Sato S
J Dermatol; 2018 Dec; 45(12):1425-1433. PubMed ID: 30289572
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Value of Krebs von den Lungen (KL-6) for Interstitial Lung Disease: A European Prospective Cohort.
Millan-Billi P; Castellví I; Martinez-Martinez L; Mariscal A; Barril S; D'Alessandro M; Franquet T; Castillo D
Arch Bronconeumol; 2024 Jun; 60(6):350-355. PubMed ID: 38644152
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis.
Kumánovics G; Minier T; Radics J; Pálinkás L; Berki T; Czirják L
Clin Exp Rheumatol; 2008; 26(3):414-20. PubMed ID: 18578962
[TBL] [Abstract][Full Text] [Related]
19. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma.
Hant FN; Ludwicka-Bradley A; Wang HJ; Li N; Elashoff R; Tashkin DP; Silver RM;
J Rheumatol; 2009 Apr; 36(4):773-80. PubMed ID: 19286849
[TBL] [Abstract][Full Text] [Related]
20. KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease.
Salazar GA; Kuwana M; Wu M; Estrada-Y-Martin RM; Ying J; Charles J; Mayes MD; Assassi S
J Rheumatol; 2018 Aug; 45(8):1153-1158. PubMed ID: 29961690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
